Press release
Odense, Denmark – February 23, 2026 – Inverna Therapeutics is pleased to announce that CEO Poul Sørensen will be presenting at the upcoming BioCapital 2026 conference organized by EQT Life Sciences (March 3-4, 2026, Amsterdam, https://www.biocapitaleuropeconference.com/ ).
Presentation details:
- Date: Wednesday, March 4, 2026
- Time: 4:40 PM
“BioCapital is the premier life science investment conference connecting biotech innovation and strategic investment. We look forward to sharing our latest progress on the development of our next-generation precision RNA splice modulation therapeutics for Parkinson’s and Huntington’s disease.”
said Poul Sørensen, CEO.
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
